Scholarlink

<p>Sacubitril/valsartan (Sac/Val) is associated with reverse cardiac remodeling in heart failure with reduced ejection fraction (HFrEF). However, the predictors of reverse cardiac remodeling after Sac/Val have not yet been fully established. We aimed to evaluate the predictors of reverse cardiac remodeling in patients with HFrEF, with a focus on HF duration and the dose of Sac/Val. In this retrospective, multicenter cohort study, 600 patients with HFrEF who received a Sac/Val prescription were enrolled at six tertiary hospitals in Korea between February 2017 and April 2019. After excluding patients without baseline or 12-month follow-up echocardiographic data, 294 patients were enrolled. Reverse cardiac remodeling was defined by comparing the baseline and follow-up echocardiographic data: an absolute increase in left ventricular ejection fraction (LVEF) ≥ 10% and a relative decrease in left ventricular end-diastolic volume index ≥ 10%. The average daily Sac/Val dose was calculated during the first 6 and 12 months after initiation. Among the 294 patients, 107 presented with reverse cardiac remodeling at 12 months. Patients with HF duration &lt; 12 months at the time of Sac/Val initiation showed a higher proportion of reverse cardiac remodeling than patients with HF duration ≥ 12 months (46.1% vs. 25.7%; <i>P</i> &lt; 0.001). Patients with an average daily Sac/Val dose ≥ 200&#xa0;mg/day over 6 months also had a higher proportion of reverse cardiac remodeling than patients with Sac/Val &lt; 200&#xa0;mg/day (44.0% vs. 31.9%; <i>P</i> &lt; 0.001). Multivariable logistic regression revealed low baseline LVEF, HF duration &lt; 12 months, and higher Sac/Val dose as independent predictors of reverse cardiac remodeling. In conclusion, early initiation of Sac/Val following HF diagnosis and higher Sac/Val doses were associated with a higher likelihood of reverse cardiac remodeling in HFrEF.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Predictors of reverse cardiac remodeling after sacubitril/valsartan in heart failure with reduced ejection fraction

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月30日

查看全文
  • Minjae Yoon,
  • Soo Young Lee,
  • Jin Joo Park,
  • Sang-Eun Lee,
  • Hyun-Jai Cho,
  • Jin-Oh Choi,
  • Byung-Su Yoo,
  • Seok-Min Kang,
  • Sue Lee,
  • Dong-Ju Choi

摘要

Sacubitril/valsartan (Sac/Val) is associated with reverse cardiac remodeling in heart failure with reduced ejection fraction (HFrEF). However, the predictors of reverse cardiac remodeling after Sac/Val have not yet been fully established. We aimed to evaluate the predictors of reverse cardiac remodeling in patients with HFrEF, with a focus on HF duration and the dose of Sac/Val. In this retrospective, multicenter cohort study, 600 patients with HFrEF who received a Sac/Val prescription were enrolled at six tertiary hospitals in Korea between February 2017 and April 2019. After excluding patients without baseline or 12-month follow-up echocardiographic data, 294 patients were enrolled. Reverse cardiac remodeling was defined by comparing the baseline and follow-up echocardiographic data: an absolute increase in left ventricular ejection fraction (LVEF) ≥ 10% and a relative decrease in left ventricular end-diastolic volume index ≥ 10%. The average daily Sac/Val dose was calculated during the first 6 and 12 months after initiation. Among the 294 patients, 107 presented with reverse cardiac remodeling at 12 months. Patients with HF duration < 12 months at the time of Sac/Val initiation showed a higher proportion of reverse cardiac remodeling than patients with HF duration ≥ 12 months (46.1% vs. 25.7%; P < 0.001). Patients with an average daily Sac/Val dose ≥ 200 mg/day over 6 months also had a higher proportion of reverse cardiac remodeling than patients with Sac/Val < 200 mg/day (44.0% vs. 31.9%; P < 0.001). Multivariable logistic regression revealed low baseline LVEF, HF duration < 12 months, and higher Sac/Val dose as independent predictors of reverse cardiac remodeling. In conclusion, early initiation of Sac/Val following HF diagnosis and higher Sac/Val doses were associated with a higher likelihood of reverse cardiac remodeling in HFrEF.